Kairos Pharma (KAPA) Stock: Buy, Sell, or Hold?
KAPA - Kairos Pharma, Ltd.
$1.76
0.08 (4.64%)
▲
5d:
+5.27%
30d:
+395.77%
90d:
+283.68%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When KAPA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: KAPA is 29.3% above its trading range ($1.36). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: KAPA is 29.3% above its trading range ($1.36). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: KAPA is currently trading at $1.76, which is considered extended relative to its 30-day fair value range of $0.08 to $1.36.
Technical Outlook: Technically, KAPA is showing sideways momentum. Immediate support is located at $0.23, while resistance sits at $1.91. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: KAPA scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+298.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KAPA is showing sideways momentum. Immediate support is located at $0.23, while resistance sits at $1.91. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: KAPA scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+298.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.08 -
$1.36
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+29.3% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.6%)
- BULLISH: Trading 298.2% below Wall St target ($7.00)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.08 -
$1.36
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.23
Resistance Level
$1.91
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.62
Wall Street Target
$7.00
(+298.2%)
Share & Embed Analysis
Last updated: September 13, 2026 11:21 AM ET
Data refreshes hourly during market hours. Next update: 12:21 PM
Data refreshes hourly during market hours. Next update: 12:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KAPA showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
